retifanlimab,bevacizumab
roche,incyte
['bevacizumab', 'radio,(-radiosarp),(-radio-sarp),(-radio sarp),(-radiol)', 'retifanlimab', 'medsir', 'roche,(-broche),(-rocheter)']
despite the initial failure of pd-1 targeting in recurrent glioblastoma, dr. jian l. campian (rochester) showed that combination of retifanlimab/hypofractionated radiotherapy/bevacizumab is well-tolerated and show encouraging mos of 12.2 months and mpfs of 9.9 months. #esmo2022 
Bring your idea to life??Creating successful IITs & optimal drug development??Medica Scientia Innovation Research????????https://t.co/cciUf0lqpM